Welcome to NUPLAZID StraightTALK
Explore this site to learn the facts about NUPLAZID® (pimavanserin)—the first and only medicine FDA-approved to treat hallucinations and delusions associated with Parkinson's disease psychosis (PDP).
In September 2023, Acadia announced a label update for NUPLAZID. Learn more
In September 2018, the FDA issued a statement reaffirming the positive benefit-risk profile of NUPLAZID for patients with hallucinations and delusions related to Parkinson's disease psychosis. Read more at FDA.gov
In September 2023, the FDA updated the NUPLAZID label to clarify its use in patients with Parkinson's disease-related hallucinations and delusions, with or without dementia, and this update is consistent with the current indication.
In September 2018, the FDA issued a statement reaffirming the positive benefit-risk profile of NUPLAZID for patients with hallucinations and delusions related to Parkinson’s disease psychosis. In addition to concluding that NUPLAZID’s benefit-risk profile for these patients remains unchanged, the FDA concluded that patients taking NUPLAZID for PDP should continue to use it as prescribed by their healthcare provider. The FDA reminds healthcare providers to be aware of the risk of QT prolongation (abnormal heart rhythm) associated with NUPLAZID, described in the prescribing information. The FDA also reminded HCPs that no other antipsychotic medication is approved for the treatment of PDP.
See additional Important Safety Information, including Boxed WARNING below